The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential.
Apoptosis
Glypican-3
Hepatocellular carcinoma
Oncogenesis
Signal transduction
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
10
05
2024
accepted:
22
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
epublish
Résumé
Glypican-3 (GPC-3) is predominantly found in the placenta and fetal liver, with limited expression in adult tissues. Its re-expression in hepatocellular carcinoma (HCC) and secretion into the serum highlights its potential as a diagnostic marker. GPC-3 is involved in important cellular processes such as proliferation, metastasis, apoptosis, and epithelial-mesenchymal transition through various signaling pathways including Wnt, IGF, YAP, and Hedgehog. To review the structure, biosynthesis, and post-translational modifications of GPC-3, and to elucidate its signaling mechanisms and role as a pro-proliferative protein in HCC, emphasizing its diagnostic and therapeutic potential. A comprehensive literature review was conducted, focusing on the expression of GPC-3 in various tumors, with a special emphasis on HCC. The review synthesized findings from experimental studies and clinical trials, analyzing the overexpression of GPC-3 in HCC, its differentiation from other liver diseases, and its potential as a diagnostic and therapeutic target. GPC-3 overexpression in HCC is linked to aggressive tumor behavior and poor prognosis, including shorter overall and disease-free survival. Additionally, GPC-3 has emerged as a promising therapeutic target. Ongoing investigations, including immunotherapies such as monoclonal antibodies and CAR-T cell therapies, demonstrate potential in inhibiting tumor growth and improving clinical outcomes. The review details the multifaceted roles of GPC-3 in tumorigenesis, including its impact on tumor-associated macrophages, glucose metabolism, and epithelial-mesenchymal transition, all contributing to HCC progression. GPC-3's re-expression in HCC and its involvement in key tumorigenic processes underscore its value as a biomarker for early diagnosis and a target for therapeutic intervention. Further research is warranted to fully exploit GPC-3's diagnostic and therapeutic potential in HCC management.
Identifiants
pubmed: 39369212
doi: 10.1186/s40001-024-02073-2
pii: 10.1186/s40001-024-02073-2
doi:
Substances chimiques
Glypicans
0
GPC3 protein, human
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
490Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis. 2019;13(1):13.
doi: 10.1002/cld.782
Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):1–3.
pubmed: 32296011
pmcid: 6946647
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85.
doi: 10.1016/j.suronc.2016.03.002
pubmed: 27312032
Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2020;111(2):334–42.
doi: 10.1111/cas.14251
pubmed: 31774932
Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers. 2019;11(9):1339.
doi: 10.3390/cancers11091339
pubmed: 31510063
pmcid: 6770328
Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease. 2019;30(2):193–200.
doi: 10.1007/s13337-019-00517-6
pubmed: 31179356
pmcid: 6531550
Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y. A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70(4):1231–45.
doi: 10.1002/hep.30646
pubmed: 30963603
Montalbano M, Georgiadis J, Masterson AL, McGuire JT, Prajapati J, Shirafkan A, Rastellini C, Cicalese L. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma. Oncol Rep. 2017;37(3):1291–300.
doi: 10.3892/or.2017.5387
pubmed: 28098909
Qi XH, Wu D, Cui HX, Ma N, Su J, Wang YT, Jiang YH. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 2014;10(6):3177–84.
doi: 10.3892/mmr.2014.2600
pubmed: 25270552
Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 2014;127(7):1565–75.
pubmed: 24496449
Reischer T, Laccone F, Kasprian GJ, Yerlikaya-Schatten G. Simpson–Golabi–Behmel-syndrome in dichorionic-diamniotic twin pregnancy. Clin Pract. 2021;11(1):75–80.
doi: 10.3390/clinpract11010012
pubmed: 33540913
pmcid: 7931115
Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol. 2014;1(35):248–52.
doi: 10.1016/j.matbio.2013.12.007
Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019;2(9):708.
doi: 10.3389/fonc.2019.00708
Shih TC, Wang L, Wang HC, Wan YJ. Glypican-3: a molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Res. 2020;4(4):168–72.
doi: 10.1016/j.livres.2020.11.003
pubmed: 33384879
pmcid: 7771890
Moek KL, Fehrmann RS, van der Vegt B, de Vries EG, de Groot DJ. Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database. Am J Pathol. 2018;188(9):1973–81.
doi: 10.1016/j.ajpath.2018.05.014
pubmed: 29935166
Chen C, Huang X, Ying Z, Wu D, Yu Y, Wang X, Chen C. Can glypican-3 be a disease-specific biomarker? Clin Transl Med. 2017;6(1):1–6.
doi: 10.1186/s40169-017-0146-5
Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trézéguet V, Sagliocco F, Hagedorn M. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget. 2017;8(25):41211.
doi: 10.18632/oncotarget.17162
pubmed: 28476031
pmcid: 5522324
Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Front Oncol. 2019;10(9):248.
doi: 10.3389/fonc.2019.00248
Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;1(168):108–18.
doi: 10.1016/j.bcp.2019.06.020
Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38(2):741–67.
doi: 10.1002/med.21455
pubmed: 28621802
Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M, Gou L, Ho M, Jia S, Chen F, Gao W. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med. 2020;18(1):1–2.
doi: 10.1186/s12967-020-02462-1
Casale J, Crane JS. Biochemistry, Glycosaminoglycans.
Ghiselli G. Drug-mediated regulation of glycosaminoglycan biosynthesis. Med Res Rev. 2017;37(5):1051–94.
doi: 10.1002/med.21429
pubmed: 28029167
Zhang L. Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog Mol Biol Transl Sci. 2010;1(93):1–7.
Kinoshita T. Glycosylphosphatidylinositol (GPI) anchors: biochemistry and cell biology: introduction to a thematic review series. J Lipid Res. 2016;57(1):4–5.
doi: 10.1194/jlr.E065417
pubmed: 26582962
pmcid: 4689333
Müller G. Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology. Mol Membr Biol. 2011;28(3):187–205.
doi: 10.3109/09687688.2011.562557
pubmed: 21413835
Kakugawa S, Langton PF, Zebisch M, Howell SA, Chang TH, Liu Y, Feizi T, Bineva G, O’Reilly N, Snijders AP, Jones EY. Notum deacylates Wnt proteins to suppress signalling activity. Nature. 2015;519(7542):187–92.
doi: 10.1038/nature14259
pubmed: 25731175
pmcid: 4376489
Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 2010;126(6):1291–301.
doi: 10.1002/ijc.24941
pubmed: 19816934
Saad A, Liet B, Joucla G, Santarelli X, Charpentier J, Claverol S, Grosset CF, Trézéguet V. Role of glycanation and convertase maturation of soluble glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry. 2018;57(7):1201–11.
doi: 10.1021/acs.biochem.7b01208
pubmed: 29345911
Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9(1):1.
doi: 10.1186/s13578-019-0342-7
Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607–16.
doi: 10.1016/j.jhep.2014.10.029
pubmed: 25450711
Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T, Kato A, Suzuki M. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biol Ther. 2009;8(24):2329–38.
doi: 10.4161/cbt.8.24.9985
pubmed: 19838081
Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):1–2.
doi: 10.1186/s13045-017-0430-2
Parayath N, Padmakumar S, Nair SV, Menon D, Amiji MM. Strategies for targeting cancer immunotherapy through modulation of the tumor microenvironment. Regen Eng Transl Med. 2020;6(1):29–49.
doi: 10.1007/s40883-019-00113-6
Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 enhances reprogramming of glucose metabolism in liver cancer cells. BioMed Res Int. 2019;2019.
Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers. 2020;12(6):1668.
doi: 10.3390/cancers12061668
pubmed: 32585931
pmcid: 7352479
Yorita K, Ohno A, Nishida T, Kondo K, Ohtomo T, Kataoka H. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res Notes. 2019;12(1):1–7.
doi: 10.1186/s13104-019-4778-y
Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG. Glypican-3 promotes epithelial–mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol. 2015;46(3):1275–85.
doi: 10.3892/ijo.2015.2827
pubmed: 25572615
Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645–54.
doi: 10.1007/s10555-016-9648-7
pubmed: 27878502
Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808.
doi: 10.1016/j.jhep.2016.05.007
pubmed: 27212245
Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M. Phase II study of the GPC-3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5(5): e1129483.
doi: 10.1080/2162402X.2015.1129483
pubmed: 27467945
pmcid: 4910752
Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocellular Carcinoma. 2016;3:63.
doi: 10.2147/JHC.S116513
Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, Yao B, Wang Y, Yang W, Liu Q, Tu K. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics. 2020;10(13):5790.
doi: 10.7150/thno.44789
pubmed: 32483419
pmcid: 7255012
Xu J, Liang J, Meng YM, Yan J, Yu XJ, Liu CQ, Xu L, Zhuang SM, Zheng L. Vascular CXCR4 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma. Clin Cancer Res. 2017;23(15):4482–92.
doi: 10.1158/1078-0432.CCR-16-2131
pubmed: 28223275
Jeng KS, Jeng CJ, Jeng WJ, Chang CF, Sheen I. Role of CXC chemokine ligand 12/CXC chemokine receptor 4 in the progression of hepatocellular carcinoma. Oncol Lett. 2017;14(2):1905–10.
doi: 10.3892/ol.2017.6396
pubmed: 28789425
pmcid: 5529928
Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J, Zeng X. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012;419(4):656–61.
doi: 10.1016/j.bbrc.2012.02.069
pubmed: 22382024
Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol. 2022;16(12): 824208.
doi: 10.3389/fonc.2022.824208
Al-Gayyar MM, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biol Chem. 2016;397(3):257–67.
doi: 10.1515/hsz-2015-0265
pubmed: 26733159
Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3–dependent Wnt activation. Hepatology. 2010;52(5):1680–9.
doi: 10.1002/hep.23848
pubmed: 20725905
Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int. 2010;30(10):1522–8.
doi: 10.1111/j.1478-3231.2010.02336.x
pubmed: 21040406
pmcid: 3042145
Hu P, Ke C, Guo X, Ren P, Tong Y, Luo S, et al. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. Dig Liver Dis. 2019;51(1):120–6.
doi: 10.1016/j.dld.2018.06.012
pubmed: 30001951
Dong Z, Yao M, Wang L, Yang J, Yao D. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem. 2014;14(14):1183–93.
doi: 10.2174/1389557515666150101105135
pubmed: 25553423
Madan B, Virshup DM. Targeting Wnts at the source—new mechanisms, new biomarkers, new drugs. Mol Cancer Ther. 2015;14(5):1087–94.
doi: 10.1158/1535-7163.MCT-14-1038
pubmed: 25901018
Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–73.
doi: 10.1038/onc.2016.304
pubmed: 27617575
Loh KM, van Amerongen R, Nusse R. Generating cellular diversity and spatial form: Wnt signaling and the evolution of multicellular animals. Dev Cell. 2016;38(6):643–55.
doi: 10.1016/j.devcel.2016.08.011
pubmed: 27676437
Kafri P, Hasenson SE, Kanter I, Sheinberger J, Kinor N, Yunger S, Shav-Tal Y. Quantifying β-catenin subcellular dynamics and cyclin D1 mRNA transcription during Wnt signaling in single living cells. Elife. 2016;23(5): e16748.
doi: 10.7554/eLife.16748
Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2016;22(5):1256–64.
doi: 10.1158/1078-0432.CCR-15-1447
pubmed: 26459179
Hong L, Cai Y, Jiang M, Zhou D, Chen L. The Hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin. 2015;47(1):46–52.
doi: 10.1093/abbs/gmu106
pubmed: 25476204
Mi L, Kuang H. Melatonin regulates cisplatin resistance and glucose metabolism through hippo signaling in hepatocellular carcinoma cells. Cancer Manag Res. 2020;12:1863.
doi: 10.2147/CMAR.S230466
pubmed: 32210629
pmcid: 7075351
Li H, Wolfe A, Septer S, Edwards G, Zhong X, Bashar Abdulkarim A, Ranganathan S, Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2012;32(1):38–47.
doi: 10.1111/j.1478-3231.2011.02646.x
pubmed: 22098159
Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, Ji X, Ji F, Gong XG, Li L, Bai X. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017;31(3):247–59.
doi: 10.1101/gad.294348.116
pubmed: 28223311
pmcid: 5358722
Li N, Spetz MR, Ho M. The role of Glypicans in cancer progression and therapy. J Histochem Cytochem. 2020;68(12):841–62.
doi: 10.1369/0022155420933709
pubmed: 32623934
pmcid: 7711243
Ngo MH, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The role of igf/igf-1r signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22(4):1931.
doi: 10.3390/ijms22041931
pubmed: 33669204
pmcid: 7919800
Cheng W, Huang PC, Chao HM, Jeng YM, Hsu HC, Pan HW, Hwu WL, Lee YM. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. Oncotarget. 2017;8(46):80429.
doi: 10.18632/oncotarget.19035
pubmed: 29113314
Wang J, Roncal OA, Ittmann MM, Ye Y. Evaluation of Glypican-3 expression in poorly differentiated carcinomas of lung origin. North Am J Med Sci. 2020;13(1).
Lee JJ, Choo SP. The fibroblast growth factor receptor pathway in hepatocellular carcinoma. Hepatoma Res. 2018;13:4.
Zheng N, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res. 2016;5(1):1.
pubmed: 27226954
Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Ther Adv Gastroenterol. 2018;11:1756284818808086.
doi: 10.1177/1756284818808086
Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P. TGF-β signalling and liver disease. he FEBS J. 2016;283(12):2219–32.
doi: 10.1111/febs.13665
Nair B, Nath LR. Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease. J Recept Signal Transduction. 2020;40(3):195–200.
doi: 10.1080/10799893.2020.1726952
Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling. Proc Natl Acad Sci. 2008;105(7):2445–50.
doi: 10.1073/pnas.0705395105
pubmed: 18263735
pmcid: 2268156